ICON Receives High Ranking in Independent Industry Survey
Dublin, Ireland, May 11th, 2009 – ICON plc,
a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has again been named as a favourite Contract Research Organisation (CRO) to work with, according to a recent independent survey of pharmaceutical and biotechnology companies.
The fourth annual “CRO Industry Update”, conducted by William Blair & Company in association with CenterWatch, surveyed executives at 19 pharmaceutical and biotechnology companies regarding their experience with CROs and general trends affecting the CRO industry. ICON was among three CROs most frequently listed as sponsors’ favourite CRO in terms of quality, a result that is in line with ICON’s high rating in William Blair’s three previous CRO surveys. The report states that “ICON is consistently rated by our survey respondents as one of the highest-quality players in the space, despite its rapid growth,” and also describes how “this consistent quality bolsters our perception that ICON has one of the best growth profiles in the CRO industry, given its solid operations and relative size.”
The survey identified the most important metrics defining quality as budget maintenance, quality deliverables and delivery within timelines, followed by regulatory expertise, flexibility, customer service and low staff turnover.
Commenting on the results, Peter Gray, CEO ICON plc said “We are delighted to be consistently viewed by clients as a CRO that delivers quality service. We work extremely hard to maintain our quality standards and these survey results are testament to the great work and expertise of ICON employees. We remain committed to developing new ways to enable clients to bring their drugs and devices to market faster.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,100 employees, operating from 71 locations in 38 countries.
Further information is available at
www.iconplc.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
